Octapharma

BAD HOMBURG, Germany and LACHEN, Switzerland - Octapharma Group and Fresenius Kabi have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi's HESylation(R) Technology to develop a HESylated recombinant protein.

LACHEN, Switzerland - Company Working With Authorities to Ensure Adequate Supply of Virally Inactivated Plasma Derivatives The impending influenza pandemic will have implications for global stocks of life-saving blood and blood products, warns Swiss-based global biopharmaceutical company, Octapharma.